ALPS Biotech 2026 Annual Meeting Highlights R&D

2026-06-25

ALPS Biotech Co., Ltd. held its 115th fiscal year annual shareholders' meeting at 10:00 a.m. on Thursday, June 25, 2026, at the company meeting room (12F-5, No. 50, Linsen N. Rd., Zhongshan Dist., Taipei), chaired by Chairman Shui-Tien Chen. The company reported its 2025 R&D progress covering three main areas — the FDA botanical drug AC04, the launch of the oral protective gel, and biomaterials production processes — reflecting its full value chain from drug development to green materials.

AC04 Botanical Drug: Exploratory Clinical Study Results

The company has completed its clinical research collaboration with National Taiwan University Cancer Center (NTUCC), covering 22 subjects with spinocerebellar ataxia. Preliminary analysis indicates statistically significant improvement in the full or selected subject populations across measures including 8-meter walk time, the 9-hole peg test, and the Hospital Anxiety and Depression Scale (HADS).

In the second half of the year, the company will complete follow-up measurements of blood inflammatory markers and EEG changes. It is also in ongoing discussions with CROs regarding the Investigational New Drug (IND) qualification for a US botanical drug application, aiming to enter formal human clinical trials after obtaining IND approval next year.

Oral Protective Gel: First-Class Medical Device Approval, Market Promotion

Developed jointly with National Defense Medical Center (NDMC), the oral liquid protective gel incorporates AL-BM002, a bioadhesive developed in-house by ALPS Biotech. It has obtained a first-class (Class I) medical device license (Ministry of Health and Welfare license no. 衛部醫器製壹字第 010530 號) and is now being promoted at medical institutions.

Looking ahead, the company plans to develop the patented bioadhesive AL-BM002 into the next generation of biomaterial-based skin tissue adhesive products, extending the technology into higher-value medical devices.

In-House Biomaterials Production Processes: Building a Sustainable Value Chain

To meet biomaterials demand, ALPS Biotech grows its own organic forage grass, AG-8, as feedstock, and has established processes to produce the biomass platform chemical 5-HMF and the bioadhesive HMVF from forage grass. The laboratory currently has kilogram-scale production capacity, with plans to advance toward a pilot plant production process.

In addition, the carbon sequestration accumulated through forage grass cultivation will be discussed with government agencies as a potential basis for future carbon credit derivatives, reinforcing the company's long-term commitment to sustainable development.

ALPS Biotech stated that its 2025 R&D results demonstrate the company's capabilities across botanical drugs, medical devices, and biomaterials. Moving forward, the company will continue to advance the AC04 clinical program, expand promotion of the oral protective gel in medical channels, and accelerate the scale-up of biomaterials production, creating long-term value for shareholders and society.